Biote CEO Christensen resigns; CFO Peterson named Interim CEO; Marc Beer Executive Chairman; FY2026 guidance reaffirmed

biote Corp.

Bret Christensen resigns as CEO effective June 8, 2026 for personal/family reasons; remains a Class III director.
CFO and Chief Business Officer Bob Peterson appointed Interim CEO and director; search for permanent CFO initiated.
Chairman Marc Beer becomes Executive Chairman with base salary of $521,200, bonus up to 85%, and option for 114,157 shares.
Company reaffirms FY2026 guidance: revenue above $190M, Adjusted EBITDA above $38M; expects procedure revenue growth in H2.
Separation agreement for Christensen includes 3-month option exercise period and 130,000-share stock option grant.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Marc Beer

Executive Chairman of the Board

BTMD · biote Corp.

Effective: 2026-06-08
Filed: June 2, 2026, 5:17 PM ET

On June 1, 2026, the Board appointed Marc Beer as Executive Chairman of the Board, effective June 8, 2026.

Departed (interim)

Bret Christensen

Chief Executive Officer

BTMD · biote Corp.

Effective: 2026-06-08
Successor: Robert Peterson
Filed: June 2, 2026, 5:17 PM ET

On May 27, 2026, the Board of Directors (the “Board”) of biote Corp. (the “Company”) accepted the resignation of Bret Christensen, the Company’s Chief Executive Officer, from his position as Chief Executive Officer of BioTE Medical, LLC (“BioTE”), effective as of June 8, 2026.

Appointed (interim)

Robert Peterson

Interim Chief Executive Officer

BTMD · biote Corp.

Effective: 2026-06-08
Filed: June 2, 2026, 5:17 PM ET

Concurrently, the Board appointed Robert Peterson, current Chief Financial Officer and Chief Business Officer of BioTE, as Interim Chief Executive Officer of BioTE to fill the vacancy created by Mr. Christensen’s resignation, and as a director of the Board, each effective June 8, 2026 (the “Effective Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Marc Beer was appointed as Executive Chairman of the Board at biote Corp..

Action: appointed
Role: Executive Chairman of the Board

Exact text from the filing

On June 1, 2026, the Board appointed Marc Beer as Executive Chairman of the Board, effective June 8, 2026.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Bret Christensen resigned as Chief Executive Officer at biote Corp..

Action: resigned
Role: Chief Executive Officer

Exact text from the filing

On May 27, 2026, the Board of Directors (the “Board”) of biote Corp. (the “Company”) accepted the resignation of Bret Christensen, the Company’s Chief Executive Officer, from his position as Chief Executive Officer of BioTE Medical, LLC (“BioTE”), effective as of June 8, 2026.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Robert Peterson was appointed as Interim Chief Executive Officer at biote Corp..

Action: appointed
Role: Interim Chief Executive Officer

Exact text from the filing

Concurrently, the Board appointed Robert Peterson, current Chief Financial Officer and Chief Business Officer of BioTE, as Interim Chief Executive Officer of BioTE to fill the vacancy created by Mr. Christensen’s resignation, and as a director of the Board, each effective June 8, 2026 (the “Effective Date”).

View on SEC.gov

biote Corp. filing history →

Source: SEC EDGAR

accession 0001193125-26-253858

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.